Highlights
- Market Cap
- $605.67M
- Enterprise Value
- $604.54M
- EPS (TTM)
- -$0.51
- EBITDA (TTM)
- -$41.54M
- Year Range
- $2.30 - $8.60
- Target Price
- $12.00
- ROA (TTM)
- -40.00%
- ROE (TTM)
- -55.29%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Alpha Tau Medical Ltd, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Alpha Tau Medical Ltd (DRTS) has returned 42.83% so far this year and 181.67% over the past 12 months.
Alpha Tau Medical Ltd
- 1D
- 7.94%
- 1M
- -8.89%
- YTD
- 42.83%
- 6M
- 56.76%
- 1Y
- 181.67%
- 3Y*
- 35.06%
- 5Y*
- -6.13%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Mar 8, 2021, DRTS's average daily return is +0.08%, while the average monthly return is +0.54%. At this rate, your investment would double in approximately 10.7 years.
Historically, 51% of months were positive and 49% were negative. The best month was Jan 2026 with a return of +40.2%, while the worst month was Aug 2022 at -30.6%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 5 months.
On a daily basis, DRTS closed higher 45% of trading days. The best single day was Jun 10, 2022 with a return of +40.2%, while the worst single day was May 11, 2022 at -25.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 40.20% | 11.82% | -8.89% | 42.83% | |||||||||
| 2025 | 19.35% | -18.38% | -16.89% | 1.99% | 16.60% | 4.52% | -1.60% | 11.40% | 31.87% | -7.65% | -4.68% | 24.69% | 59.68% |
| 2024 | 10.30% | -9.64% | -1.67% | -15.25% | 0.40% | 0.80% | -13.83% | 12.39% | -2.86% | -1.68% | 19.66% | 10.71% | 2.99% |
| 2023 | 25.16% | -20.60% | -9.18% | 6.62% | 29.74% | 10.08% | -9.38% | -17.17% | 15.55% | -5.01% | -8.89% | -8.23% | -5.35% |
| 2022 | 1.63% | 9.32% | 8.16% | -27.80% | -9.15% | 16.41% | 22.09% | -30.55% | -23.56% | -28.08% | -5.00% | -20.30% | -67.62% |
| 2021 | -4.36% | 0.72% | -0.92% | 0.10% | 1.87% | 0.20% | 0.10% | 0.71% | -0.00% | -1.11% | -2.77% |
Benchmark Metrics
Alpha Tau Medical Ltd has an annualized alpha of 15.88%, beta of 0.51, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since March 09, 2021.
- This stock participated in 146.60% of S&P 500 Index downside but only 75.51% of its upside — more exposed to losses than it benefited from rallies.
- Beta of 0.51 may look defensive, but with R² of 0.01 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 15.88%
- Beta
- 0.51
- R²
- 0.01
- Upside Capture
- 75.51%
- Downside Capture
- 146.60%
Return for Risk
Risk / Return Rank
DRTS ranks 94 for risk / return — in the top 94% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Alpha Tau Medical Ltd (DRTS) and compare them to a chosen benchmark (S&P 500 Index).
| DRTS | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 2.83 | 0.90 | +1.93 |
Sortino ratioReturn per unit of downside risk | 3.30 | 1.39 | +1.92 |
Omega ratioGain probability vs. loss probability | 1.40 | 1.21 | +0.19 |
Calmar ratioReturn relative to maximum drawdown | 7.38 | 1.40 | +5.98 |
Martin ratioReturn relative to average drawdown | 19.56 | 6.61 | +12.95 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore DRTS risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Alpha Tau Medical Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Alpha Tau Medical Ltd was 86.86%, occurring on Aug 6, 2024. The portfolio has not yet recovered.
The current Alpha Tau Medical Ltd drawdown is 53.79%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -86.86% | Mar 30, 2022 | 591 | Aug 6, 2024 | — | — | — |
| -28.34% | Mar 8, 2022 | 2 | Mar 9, 2022 | 11 | Mar 24, 2022 | 13 |
| -11.68% | Mar 9, 2021 | 236 | Feb 10, 2022 | 7 | Feb 22, 2022 | 243 |
| -10.12% | Feb 23, 2022 | 2 | Feb 24, 2022 | 1 | Feb 25, 2022 | 3 |
| -7.52% | Mar 25, 2022 | 1 | Mar 25, 2022 | 2 | Mar 29, 2022 | 3 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Alpha Tau Medical Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Alpha Tau Medical Ltd is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for DRTS in comparison with other companies in the Biotechnology industry. Currently, DRTS has a P/B value of 7.9. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |